Smooth Muscle Myosin Heavy Chain Expression in Nodal and Extranodal Follicular Dendritic Cell Sarcoma

Area of Science:

• Oncology
• Immunohistochemistry
• Pathology

Background:

• Follicular dendritic cell sarcoma (FDCS) is a rare cancer.
• Diagnosis can be challenging, particularly with small biopsy samples.
• Established markers for follicular dendritic cells (FDCs) include CD21, CD23, fascin, clusterin, and D2-40.

Purpose of the Study:

• To evaluate the utility of smooth muscle myosin heavy chain (SMMHC) as an immunohistochemical marker for FDCS.
• To compare the performance of SMMHC with established FDC markers in diagnosing FDCS.
• To assess the specificity of SMMHC in differentiating FDCS from other neoplastic conditions.

Main Methods:

• Retrospective review of seven archival cases of nodal and extranodal FDCS.
• Immunohistochemical staining for SMMHC and established FDC markers (CD21, CD23, fascin, clusterin, D2-40).
• Evaluation of SMMHC staining in 14 cases of common differential diagnoses for FDCS.

Main Results:

• SMMHC staining was positive in five out of seven FDCS cases.
• SMMHC demonstrated similar sensitivity to established markers like clusterin, CD21, and CD23.
• SMMHC was negative in all examined cases of potential mimics, indicating high specificity.

Conclusions:

• Smooth muscle myosin heavy chain (SMMHC) is a sensitive and specific immunohistochemical marker for follicular dendritic cell sarcoma (FDCS).
• SMMHC can be a valuable addition to the diagnostic panel for FDCS, aiding in the differentiation from other tumors.
• Its common availability and performance make SMMHC a practical tool in evaluating FDCS and its mimics.